Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment
Executive Summary
Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.
You may also be interested in...
Nestlé Health Science Refocuses As It Drops Peanut Allergy Treatment
VMS, active nutrition and medical nutrition will be Nestle Health Science's main focus areas going forward with the business looking to offload peanut allergy treatment Palforzia. The Swiss firm announced the move as it reported organic growth of 4% at Health Science for 2022.
Nestle Harvests Plant-Based Protein Firm Orgain As Latest US Nutrition Business Investment
Nestle Health Science has expanded its nutritional footprint steadily since 2017 but investing in Orgain, with option to fully acquire in 2024 brings its first business working exclusively with plant-based ingredients.
Demand For Immunity Boosters Lifts Nestlé Health Science
Nestlé Health Science saw sales rise double digits in 2020 thanks to higher demand for health and immunity products during the pandemic.